Ultime notizie per Immix Biopharma (NASDAQ:IMMX) Azioni

Immix Biopharma

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Immix Biopharma Inc

V2X Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) announced Monday that it has <a href="/www.benzinga.com/pressreleases/25/04/n45035761/v2x-awarded-103-million-u-s-navy-contract-for-c-26-support-extending-legacy-as-a-readiness-multipl" target="_blank" rel="noreferrer noopener">secured a $103 million contract</a> from the U.S. Navy to deliver Contractor Logistics Support (CLS) services for the Navy&#8217;s C-26 aircraft fleet.
The agreement further cements V2X&#8217;s reputation as a trusted partner in ensuring operational aircraft readiness and mission success.
As part of the newly awarded contract, V2X will continue to provide critical support services, covering engineering, aircraft upgrades, maintenance, and modifications. This latest development reinforces the Navy&#8217;s faith in the company&#8217;s capabilities.
Jeremy C. Wensinger, President and CEO of V2X, expressed that the contract win underscores the Navy&#8217;s enduring confidence in V2X&#8217;s ability to maintain superior aircraft performance standards. &#8220;This award highlights the Navy&#8217;s continued confidence in V2X&#8217;s proven ability to deliver mission-capable aircraft with exceptional performance,&#8221; Wensinger said.
The contract, structured as a firm-fixed-price agreement, will officially commence in June 2025. It covers maintenance and support for eight C-26A/D aircraft located at four primary bases—one domestic and three international facilities.
Earlier in April, V2X secured a <a href="https://www.benzinga.com/pressreleases/25/04/n44681707/v2x-delivering-critical-support-to-u-s-missile-defense-and-space-surveillance-capabilities" target="_blank" rel="noreferrer noopener">$62 million contract</a> extension to maintain and enhance the COBRA DANE radar in Alaska, reinforcing its critical role in U.S. Space Force missile defense and space domain awareness through 2027.
<h2 class="wp-block-heading">VVX Stock Prediction For 2025</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of V2X have an average 1-year price target of $62.25, representing an expected upside of 25.37%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on V2X, while 3 analysts have bullish ratings. The street high price target from Citizens Capital Markets is $80.0, while the street low from RBC Capital is $54.0.
Price Action: VVX shares are traded lower by 0.34% at $49.64 at the last check on Monday.
Photo by AU USAnakul via Shutterstock

News

Contracts

V2X Lands $103 Million Navy Aircraft Support Contract

Cryptocurrency markets are trading sideways on Monday, following a strong previous week that saw Bitcoin reclaim the $94,000 level.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$94,117</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$1,771</td>
<td>-1.8%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$146.87</td>
<td>-2.0%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.28</td>
<td>+1.5%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1761</td>
<td>-2.6%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.0000136</td>
<td>+01%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume up by 6.2% and daily active addresses down by 0.7%. </li>
<li>Coinglass data reports 115,648 traders were liquidated in the past 24 hours for $271.87 million.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45034209/bitcoin-could-hit-120000-in-q2-says-standard-chartereds-geoff-kendrick">Bitcoin Could Hit $120,000 In Q2, Says Standard Chartered&#8217;s Geoff Kendrick</a></li>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/04/45039498/sec-approves-proshares-xrp-futures-etfs-xrp-price-surges-ahead-of-launch">SEC Approves ProShares XRP Futures ETFs: XRP Price Surges Ahead Of Launch</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45039243/xrp-is-the-top-altcoin-bet-10x-research">XRP Is The Top Altcoin Bet: 10x Research</a></li>
<li><a href="https://www.benzinga.com/25/04/45046221/pudgy-penguins-coin-pengu-outperforms-dogecoin-shiba-inu-with-123-weekly-gain">Pudgy Penguins Coin PENGU Outperforms Dogecoin, Shiba Inu With 123% Weekly Gain</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45048427/watch-this-bitcoin-indicator-to-know-if-a-run-to-100000-is-coming">Watch This Bitcoin Indicator To Know If A Run To $100,000 Is Coming</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Virtuals Protocol (CRYPTO: VIRTUAL)</td>
<td>&nbsp;$1.36</td>
<td>+25.6%</td>
</tr>
<tr>
<td>Monero (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xmr/usd">XMR</a>)</td>
<td>&nbsp;$257.21</td>
<td>+11.8%</td>
</tr>
<tr>
<td>Bittensor (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TAO</a>)</td>
<td>&nbsp;$372.71</td>
<td>+6.3%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Prominent trader &#8220;Inmortal&#8221; says the most likely scenario for Bitcoin, in case it holds the $90,000 level, is a period of sideways trading, followed by another uptrend in June.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The most likely scenario if we hold above 90k<a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> <a href="https://t.co/z4jHBmJkNS">pic.twitter.com/z4jHBmJkNS</a>
&mdash; Inmortal (@inmortalcrypto) <a href="https://twitter.com/inmortalcrypto/status/1916906045508661371?ref_src=twsrc%5Etfw">April 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Jelle <a href="https://x.com/CryptoJelleNL/status/1916880982923465103">opines</a> that as long as Bitcoin holds above $94,000, it could test the $100,000 level in the next days.
Prominent analyst Kevin highlighted the golden pocket level around $95,300 as a key resistance to be overcome. Bitcoin has been trading around this level for several days.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45017648/bitcoin-climbs-12-on-the-week-as-traders-eye-run-to-100000">Bitcoin Climbs 12% On The Week As Traders Eye Run To $100,000</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$TAO

$XMR

$XRP

Bitcoin Ethereum XRP Dogecoin Hold Firm After Last Week's Rally: What's Next

As Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) showed in its <a href="https://www.benzinga.com/news/25/04/45039495/dominos-pizza-q1-operating-margin-shrinks-as-lower-income-consumers-feel-the-pinch">latest earnings report</a>, even America's favorite comfort food is not immune to the chill of a cooling economy. High inflation and jittery consumer sentiment, spooked by erratic trade policies, pulled down U.S. same-store sales by 0.5% on-year in the first quarter — a surprise miss against expectations.
Yet, all is not burnt crust and bad news. Domino&#8217;s surpassed earnings estimates with an EPS of $4.33, compared to $3.58 in the same quarter last year.
Smart tech investments by Domino&#8217;s, such as AI-based order preparation and their AnyWare platform, are likely to keep holding investor faith. On top of that, its new agreement with DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>), which is launching nationwide in May, Domino&#8217;s has laid the groundwork for a possible comeback in the second half of the year.
This resiliency might make <a href="https://www.benzinga.com/etfs">ETFs holding restaurant stocks</a> an excellent opportunity for investors seeking to ride out economic volatility. Funds exposed to names such as Domino&#8217;s, McDonald&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), and Chipotle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>)—all firms focusing on tech development and value-for-money strategies—may provide a defensive yet lively play.
The following are three ETFs that investors may consider adding to their menu:
AdvisorShares Restaurant ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EATZ#NYSE">EATZ</a>)
EATZ is the sole pure-play restaurant ETF in the U.S. market, providing direct exposure to quick-service behemoths such as Domino&#8217;s, McDonald&#8217;s and Chipotle.
With a diversified basket in fast food, casual dining and coffee chains, EATZ is for those who think Americans will hold on to their comfort food, recession or not.
Domino&#8217;s is one of its top holdings, making it a natural choice for those wagering on pizza&#8217;s staying power.
However, EATZ has a reasonably small asset base, which may result in thinner liquidity. This makes it best suited for investors with a slightly higher tolerance for volatility.
Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)
XLY provides more extensive exposure to consumer discretionary names, with heavyweight positions in Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), but also brings in big restaurant players such as McDonald&#8217;s and Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>).
It&#8217;s less restaurant-intensive but gives more diversification to investors who desire dining stocks without going &#8220;all in&#8221; on the group.
During turbulent markets, the power of familiar names can be like economic comfort food, reassuring but with less risk.
Invesco Dynamic Leisure and Entertainment ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEJ#NYSE">PEJ</a>)
PEJ follows U.S. leisure and entertainment companies — including large restaurant chains.
It tilts toward companies poised for consumer discretionary spending, picking up both restaurants and entertainment spots.
US Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) and others typically have a spot on its list, surfing trends such as value-based dining and convenience-optimized ordering like DoorDash.
PEJ&#8217;s high-momentum selection strategy aims to pick up companies with good fundamentals and momentum, making it a good choice in turbulent economic climates.
It is interesting to note that the <a href="https://www.benzinga.com/topic/warren-buffett">recent action by Warren Buffett&#8217;s</a> Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) to <a href="https://www.benzinga.com/content/44975325/2-smart-investments-to-follow-warren-buffetts-lead">raise its stake in Domino&#8217;s in Q3 2024</a>, just ahead of the latest tariff-led market volatility further supports the notion: even when the economy is shaken like a pizza, innovation, value and customer loyalty can make the dough keep coming.
For ETF investors, this could be the time to try restaurant-themed or consumer-discretionary funds that serve up a full plate of durability. After all, when pocketbooks get tight, Americans might skip the gourmet meal — but they&#8217;ll still call for a $10 pizza, maybe with extra cheese.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/04/45047236/etfs-last-week-funds-lead-the-charge-as-markets-stage-a-return-to-risk-on">ETFs Last Week: Funds Lead The Charge As Markets Stage A Return To Risk-On</a></li>
</ul>
Photo: Shutterstock

Earnings Misses

Specialty ETFs

ETFs

AMZN

DASH

EATZ

PowerShares ETF Leisure & Entertainment Port

SBUX

TSLA

USFD

Select Sector SPDR-Consumer Discretionary

Domino's Pizza Earnings Miss: 3 ETFs That Could Still Deliver Tasty Returns In 2025

Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. This represents the third clinical study evaluating botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting, with outcomes reported in mismatch repair–proficient (pMMR/MSS) and mismatch repair–deficient (dMMR/MSI-H) solid tumors. These findings include the first reported outcomes with BOT/BAL outside colorectal cancer in the neoadjuvant setting.

AGEN

Agenus: Initial Results From NEOASIS Show BOT/BAL Efficacy In Neoadjuvant Setting Across Multiple MSS And MSI-H Solid Tumors

We've been getting&nbsp;<a href="https://www.tker.co/p/economic-data-earnings-results-ambiguous">ambiguous signals in the economic data</a>.
On one hand, the soft, sentiment-oriented data has been disappointing. The&nbsp;<a href="https://www.sca.isr.umich.edu/">University of Michigan</a>&nbsp;and the&nbsp;<a href="https://www.conference-board.org/topics/consumer-confidence">Conference Board's</a>&nbsp;surveys of consumer confidence have turned sharply lower in recent months. The&nbsp;<a href="https://www.nfib.com/wp-content/uploads/2025/04/NFIB-SBET-Report-March-2025.pdf">NFIB's Small Business Optimism index</a>&nbsp;has tanked. Sentiment among&nbsp;<a href="https://www.apolloacademy.com/corporate-confidence-declining/">CEOs and CFOs</a>&nbsp;has turned south. Purchasing managers at&nbsp;<a href="https://www.ismworld.org/globalassets/pub/research-and-surveys/rob/pmi/t4rf202503pmi.pdf">manufacturing</a>&nbsp;and&nbsp;<a href="https://www.ismworld.org/globalassets/pub/research-and-surveys/rob/nmi/5tagrob202503svcs.pdf">services</a>&nbsp;firms have also become increasingly cautious. And it's all because of the Trump administration's volatile position on tariffs — which most people&nbsp;<a href="https://www.tker.co/p/wall-street-brief-explanation-tariffs">agree are net negative for the economy</a>.
On the other hand, the hard data, which reflects actual activity, has been strong. <a href="https://www.tker.co/i/161227758/review-of-the-macro-crosscurrents">Retail sales</a> hit a record high in March, and weekly card spending data suggest that strength has continued into April. Durable goods orders and shipments continue at elevated levels. Meanwhile, key labor market metrics including job creation, unemployment, and claims for unemployment insurance continue to trend at levels associated with economic expansion.
This narrative of contradictions is illustrated nicely in this chart from Goldman Sachs, which shows how soft data has been surprising to the downside while hard data has been surprising to the upside. In other words, sentiment has been weaker than expected while realized activity has been stronger than expected.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F50658b33-5637-46a3-8c08-631f0ee9807a_1746x1288.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F50658b33-5637-46a3-8c08-631f0ee9807a_1746x1288.png" alt="" title="" /></a><figcaption class="wp-element-caption">The hard data has been surprisingly good despite the soft data being surprisingly bad. (Source: Goldman Sachs)</figcaption></figure>
Renaissance Macro's Neil Dutta wrote about these "data discontinuities" in his April 21 note.
"It's probable that much of the recent upside surprises in hard data reflect pulling forward activity in the anticipation of tariffs," Dutta wrote. "Consumers pulled forward auto sales and consumption on other household durables, as an example. Firms likely pulled forward some orders too. That likely gives the veneer of strength in the recent high-frequency dataflow."
During much of the economic expansion that began in 2020, it's paid off to focus on what&nbsp;<a href="https://www.tker.co/p/october-retail-sales-strong-sentiment-inflation">consumers</a>&nbsp;and&nbsp;<a href="https://www.tker.co/p/weekly-macro-soft-vs-hard-data">businesses</a>&nbsp;did (i.e., the hard data) over what they said (i.e., the soft data). The Federal Reserve&nbsp;<a href="https://www.federalreserve.gov/econres/notes/feds-notes/tracking-consumer-sentiment-versus-how-consumers-are-doing-based-on-verified-retail-purchases-20250424.html">just published research</a>&nbsp;explaining this phenomenon.
But in a world where many are&nbsp;<a href="https://www.tker.co/p/sales-pull-forward-frontrunning-tariffs">aware of the inflationary risks of new tariffs</a>, this&nbsp;<a href="https://www.tker.co/p/economic-data-earnings-results-ambiguous">pull-forward of sales</a>&nbsp;comes with two issues: 1) it masks what may be a much&nbsp;<a href="https://www.tker.co/p/hot-economic-charts-that-cooled">weaker underlying economy</a>, and 2) we could get&nbsp;<a href="https://www.tker.co/i/158036475/brace-for-payback">depressed sales in the future</a>&nbsp;when these pulled-forward sales would've normally occurred.
"[R]ecent hard data in the U.S., mostly for March, are overstating activity and it's worth noting that conditions were not especially strong to begin with," Dutta added. "The collapse across a range of survey-based measures of activity suggest that actual activity will continue to slowdown, in a potentially abrupt manner. Recession may already be here."
<h2 class="wp-block-heading">The big picture &#x1f5bc;&#xFE0F;</h2>
We'll only know with the benefit of hindsight whether or not we're in a recession or going into a recession.
However, we know that&nbsp;<a href="https://www.tker.co/p/hot-economic-charts-that-cooled">the economy had been cooling</a>&nbsp;and that the threat of tariffs&nbsp;<a href="https://www.tker.co/p/stock-market-history-with-recessions">increased the risk of recession</a>.
Importantly, as long term investors, we should understand that&nbsp;<a href="https://www.tker.co/p/stock-market-history-with-recessions">recessions</a>&nbsp;and&nbsp;<a href="https://www.tker.co/p/bear-markets-in-context">market downturns</a>&nbsp;will happen as you build wealth with stocks.
The economy has been in expansion&nbsp;<a href="https://www.tker.co/i/135828032/most-actual-news-about-the-economy-and-the-stock-market-isnt-bad">about 80% of the time</a>. Similarly, stocks have been in a bull market&nbsp;<a href="https://www.tker.co/i/135828032/most-actual-news-about-the-economy-and-the-stock-market-isnt-bad">about 80% of the time</a>. Maybe we're currently going through an unpleasant period that has historically occurred about 20% of the time.
<h4 class="wp-block-heading">&#x2A;&#x2A;</h4>

Equities

Econ #s

Opinion

Markets

Trading Ideas

Ambiguous Signals In Economic Data

On Friday, AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported an adjusted EPS of $2.46, up 6.5% year over year and beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.38</a>.
The pharmaceutical giant reported sales of $13.34 billion, up 8.4% on a reported basis (+9.8% on an operational basis), beating the <a target="_blank" href="https://www.benzinga.com/25/04/45011116/abbvie-q1-earnings-come-ahead-of-expectations-ceo-says-well-positioned-for-long-term" rel="noreferrer noopener">consensus of $12.92 billion</a>.
It reported adjusted earnings per share of $2.46, beating the street view of $2.38.
BMO Capital Markets writes that every quarter seems to tell the same story. Analysts think they&#8217;ve accurately factored in Skyrizi and Rinvoq&#8217;s growth, only for AbbVie to outperform expectations once again.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44937940/abbvies-pipeline-may-be-a-2026-story-but-analyst-likes-the-setup-now" rel="noreferrer noopener">AbbVie&#8217;s Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now</a>
In the first quarter of 2025, Skyrizi and Rinvoq beat consensus estimates by 7% and 8%, respectively.
<ul>
<li>Skyrizi sales increased 70.5% (+72%) to $3.425 billion.</li>
<li>Rinvoq sales reached $1.72 billion, an increase of 57.2% (+59.7%).</li>
</ul>
&#8220;While we are still carefully watching the launch of Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Tremfya as it begins to build momentum, 1Q25 demonstrated the prowess of AbbVie&#8217;s commercial contracting team again, pushing us to again revise our estimates higher for the two products. With Skyrizi now capturing 1 in 3 in place UC patients, we highlight that the company&#8217;s I&amp;I portfolio appears poised to continue growing through more significant Humira erosion,&#8221; analyst Evan David Seigerman writes.
Seigerman writes that AbbVie appears well-positioned to manage through Humira&#8217;s U.S. patent loss. With the acquisition of ImmunoGen and Cerevel, AbbVie is well-positioned to capitalize on Elahere&#8217;s growth and key readouts for emeraldine/tavapadon.
Vyalev was a minor contributor to AbbVie&#8217;s overall beat, but BMO Capital writes that investors may be underappreciating its growth and upside. With Medicare reimbursement not yet in place, the analyst sees more upside to analyst estimates over the coming quarters. Advancements with Vyalev appear to pair well with Cerevel&#8217;s tavapadon, which could also be commercialized in 2026, meaningfully expanding the company&#8217;s Parkinson&#8217;s portfolio.
Vyalev is&nbsp;a prescription medication used to treat motor fluctuations in adults with advanced Parkinson&#8217;s disease.
<ul>
<li>BMO maintains the Outperform rating and a <a href="https://www.benzinga.com/quote/ABBV/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $215</a>.</li>
<li>Morgan Stanley maintains AbbVie with an Overweight, raising the price target from $241 to $250.</li>
<li>Evercore ISI Group keeps the Outperform rating for AbbVie, raising the price target from $204 to $205.</li>
</ul>
Price Action: ABBV stock is up 2.54% at $190.79&nbsp;at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44950727/bristol-myers-cobenfy-falls-short-on-primary-endpoint-in-phase-3-schizophrenia-trial" target="_blank" rel="noreferrer noopener">Bristol Myers&#8217; Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Earnings

Large Cap

Guidance

Health Care

Analyst Ratings

General

ABBV

AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst

<a href="https://www.bloomberg.com/news/articles/2025-04-28/ups-in-talks-with-startup-figure-ai-to-deploy-humanoid-robots" title="https://www.bloomberg.com/news/articles/2025-04-28/ups-in-talks-with-startup-figure-ai-to-deploy-humanoid-robots">https://www.bloomberg.com/news/articles/2025-04-28/ups-in-talks-with-startup-figure-ai-to-deploy-humanoid-robots</a>

'UPS In Talks With Startup Figure AI To Deploy Humanoid Robots' - Bloomberg News

Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>)&nbsp;is <a target="_blank" href="https://www.benzinga.com/topic/sony" rel="noreferrer noopener">weighing spinning off</a> its semiconductor unit Sony Semiconductor Solutions Corp.
The spinoff and listing of the&nbsp;semiconductor unit&nbsp;may occur by 2025.
Sony is considering distributing most of its holding in the chip business and may retain a minority holding after the spinoff, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-28/sony-is-said-to-mull-chip-spinoff-that-loeb-called-for-years-ago?sref=TBDibEcD" rel="noreferrer noopener">reported</a> Monday, citing unnamed sources familiar with the matter.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44787792/sony-raises-ps5-prices-in-some-countries-by-up-to-25-in-anticipation-of-tariffs" rel="noreferrer noopener">Sony Raises PS5 Prices In Some Countries By Up To 25% In Anticipation Of Tariffs</a>
Sony is also planning to spin off <a href="https://www.benzinga.com/news/23/05/32459765/sony-shares-are-surging-premarket-company-eyes-sony-financial-arm-ipo" target="_blank" rel="noreferrer noopener">its financial arm</a>, Sony Financial Group Inc, in line with investor Dan Loeb's plans to unlock value.
Sony reported <a target="_blank" href="https://www.benzinga.com/25/02/43700230/sony-q3-earnings-beats-expectations-raises-outlook-as-ps5-sales-and-streaming-revenues-climb" rel="noreferrer noopener">fiscal third-quarter</a> 2024 consolidated sales&nbsp;growth&nbsp;of 18% to $28.97 billion (4.41 trillion Japanese yen), topping the&nbsp;analyst consensus estimate of&nbsp;$23.78 billion.&nbsp;EPS of $0.41 (61.82 yen) beat the&nbsp;analyst consensus estimate of $0.30.
Consolidated operating income rose by 1% to ¥469.3 billion. Game &amp; Network Services operating income climbed 37%&nbsp;to&nbsp;¥118.1 billion. Music operating income increased by 28%&nbsp;to ¥97.4 billion. Pictures operating income declined by 18% to ¥34.0 billion. Entertainment, Technology, &amp; Services operating income remained flat at ¥77.1 billion.&nbsp;Imaging &amp; Sensing Solutions operating income declined 2%&nbsp;to ¥97.5 billion. Financial Services operating income decreased by 40% to ¥46.4 billion.
Sony expects fiscal 2024 sales of $88.00 billion or ¥13.20 trillion versus&nbsp;the&nbsp;$81.59 billion consensus.&nbsp;
Recently, Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) announced a&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44828811/intel-growth-challenges-are-not-over-despite-altera-stake-sale-analyst" rel="noreferrer noopener">51% stake sale</a>&nbsp;of its programmable chip business, Altera, to private equity firm Silver Lake Management for $4.46 billion, valuing Altera at $8.75 billion. Intel originally acquired Altera for $16.7 billion in December 2015.
Price Action: SONY stock traded higher by 0.6% to $25.11 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43052360/sony-cancels-two-live-service-games-stays-committed-to-long-term-monetization" target="_blank" rel="noreferrer noopener">Sony Cancels Two Live-Service Games, Stays Committed to Long-Term Monetization</a></li>
</ul>
Photo: testing/Shutterstock

Media

INTC

Sony Group Corporation American Depositary Shares

SONY

What's Pushing Sony To Consider A Semiconductor Spinoff?

Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares are trading lower Monday. Oppenheimer analyst Jason Helfstein maintained an Outperform rating on Amazon but lowered the price target from $260 to $220.
What To Know: Helfstein reduced estimates ahead of the company&#8217;s upcoming earnings report, citing uncertainty around the impact of tariffs on the e-commerce industry.
He believes third-quarter results will be hit the hardest, as Amazon sellers still have inventory purchased before tariffs took effect.
Amazon CEO Andy Jassy told CNBC some sellers are buying inventory ahead of time, with consumers also making purchases before expected price increases. Sellers are likely to pass higher tariff costs onto consumers, although no major shifts in behavior have been seen yet.
Helfstein lowered overall revenue estimates by 2% for fiscal-year 2025 and 1% for fiscal-year 2026, matching the reductions to North America forecasts. He also cut international revenue projections by 2% and Amazon Web Services revenue by 1%.
The analyst also cut EBIT estimates, expecting total EBIT to fall 19% in fiscal-year 2025 and 14% in fiscal-year 2026. North America EBIT is projected to drop 49% in 2025 and 35% in 2026, while International EBIT and Amazon Web Services EBIT are expected to decline 2% and 1%, respectively.
See Also: <a href="https://www.benzinga.com/news/25/04/45049101/toyota-eyes-major-shakeup-with-42-billion-offer-for-toyota-industries">Toyota Eyes Major Shakeup With $42 Billion Offer For Toyota Industries</a>
AMZN Price Action: At the time of writing, Amazon shares are trading 1.10% lower at $186.92, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

Movers

Oppenheimer's Helfstein Cuts Amazon Price Target To $220 On Tariff Concerns

There's little doubt the tariff wars have taken a toll on Americans' investment portfolios. And with the markets still in disrepair, nobody knows when stocks will stabilize.
"The situation is volatile, to say the least," said Doug Carey, a financial advisor at WealthTrace, a retirement planning consumer software company. "President Trump has the final word on how much tariffs will cost because he is using emergency powers, citing the International Emergency Economic Powers Act (IEEPA), passed in 1977. These moves may be struck down in court, but for now, he can use them."
To peg a reasonable timeframe, Benzinga reached out to select market experts for their views on a permanent "ceasefire" in the tariff wars, which could help calm anxious investors and encourage them to return to the market.
Here's what they had to say on when the markets will come back to sanity.
Doug Carey: There will likely be several signs that the market is set to rebound after the tariff issue is settled &#8211; or at least stabilized. "Look for the stock market to rise substantially and for the dollar to strengthen," Carey said. "Gold, which has increased over 25% this year due to the fear of a larger trade war, will do poorly if the tariff drama ends."
Carey said technology stocks were hurt the most by the fear of a trade war. "For those who believe that there will be an end to this drama soon, the tech sector is a good place to invest," he added.
Javier Palomarez, founder &amp; CEO of the United States Hispanic Business Council: "The clearest signal would be a statement from the Trump Administration that the tariffs are being walked away from, as a result of negotiations or whatever the case may be," Palomarez said. "However, it's worth noting that declining stocks also represent robust opportunities. Ideally, one would purchase their investments just before such a statement."
Palomarez advises investors to be vigilant about watching tariff trends – you don't want to miss the market rebound.
"If investors sold their stock at the low, it's critical to purchase it back before the market fully reacts to the signal that everything is clear, especially if you plan on investing in stocks that are vulnerable to future tariffs and regulations," Palomarez added. "Some investors may want to consider index funds or stocks in industries that are insulated from such rapid changes and regulatory uncertainty."
Chuck Zhang, CFO of PolyFlow, a decentralized payments company in Fair Lawn, N.J.: Last week, President Trump hinted at a possible shift in his trade stance with China, suggesting that the steep tariffs on Chinese imports will be substantially reduced. "His comments signal a softening in tone following weeks of escalating rhetoric and retaliatory measures that had driven tariffs on Chinese goods to over 145%," Zhang said. "While this would be a positive development in terms of de-escalation, the overarching trade policy remains assertive, contributing to the recent market volatility."
Zhang said he would advise investors to monitor several variables. "We're looking at a definitive resolution or rollback of tariffs; sustained rallies in equity markets, drops in the VIX volatility index, especially in sectors previously affected by tariffs; and overall improvements in global trade volumes, manufacturing indices, and corporate earnings," he said.
Investors should simultaneously evaluate asset allocations to achieve alignment with their long-term financial goals, considering a diversified mix of equities, bonds and other assets.​ "Then, as a general rule, prioritize investments in companies with strong balance sheets and consistent earnings," Zhen advised.
Jeff Weniger, head of equity strategy at the asset management firm Wisdom Tree: Weniger suspects the tariff issue is at the stage where the most aggressive bargaining chips are being methodically pulled off the table. "For example, India and Japan are priced at 84% and 77% probabilities, respectively, of coming to a trade deal with the Trump administration by July," he said. "Though other countries' probabilities are priced lower (China is 42%), this is a far cry from some of the intense pessimism that was being priced in earlier this summer."
For now, though, the worst of the drama is likely over. "The peak risk in markets was the 145% tariff on China, with similar reciprocity," Weniger added. "Those figures have been coming down for a few weeks, as has the tone of commentary from both the White House and Beijing."
Wenger also advised investors to keep an eye on volatility gauges such as the VIX index. "That index headed north of 60 on April 7th, a level of fear akin to readings that registered right after 9/11 and amid the bank and insurance company failures of late 2008," he added. "Fear levels on that order often precipitate heady gains in stocks."
<h2 class="wp-block-heading">Play The Tariff Game To Your Advantage</h2>
Other market experts say there is no clear sign that indicates the end of the tariff drama.
"This situation is not like a typical economic cycle with predictable patterns," said Julia Khandoshko, CEO at Mind Money, an international brokerage firm. "Instead, it resembles a new phase in global economics — what might one day be known as the &#8216;Tariff Wars of the 21st Century.'&#8221;
Khandoshko believes investors shouldn't wait for an obvious turning point, because one may never come. "Rather than looking for a specific event or announcement, they should integrate tariff risks into their long-term strategy," she said. "This means evaluating how particular companies might be impacted if tariffs are imposed on their goods or services."
Others agree, adding that tampering with the nation's Treasury market is a bad idea going forward.
"There may not be an &#8216;all clear&#8217; signal on tariffs because of politics," said David Russell, global head of market strategy at TradeStation Group in Chicago. "Officials may quietly backpedal on them without a lot of publicity. This crisis started with a bang, but it might end with a whimper."
Russell also offers a "lessons learned" factor for investors to absorb when the tariff-related carnage is over.
"Investors have learned that the bond market matters," he noted. "Our system relies on a functioning Treasury market, which requires a degree of foreign participation. Undermining that system threatens the foundation of the stock market and the entire economy."
<h2 class="wp-block-heading">Turn Earnings Reports Into Trading Opportunities</h2>
Over 160 companies reported earnings recently, including Walmart, Alibaba, and Rivian. Benzinga Edge gives you instant access to earnings surprises, market-moving insights, and expert-driven strategies to act fast. Unlock Your Edge <a href="https://www.benzinga.com/premium/ideas/benzinga-edge">HERE</a>
Editorial content from our Expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Exclusives

Interview

How You'll Know When Tariff Troubles Are Finally Over

PBYI

Puma Biotechnology Presents Clinical Data Of Phase I Trial Of trastuzumab deruxtecan In Combination With Neratinib In Solid Tumors With HER2 Alterations At AACR 2025

The <a href="https://www.benzinga.com/general/sports/25/04/44990571/2025-nfl-draft-how-to-watch-betting-odds-will-record-first-round-happen">2025 NFL Draft</a> is complete, and attention turns to how rookies will factor into their new team's depth charts for the next season.
Here's a look at the early Rookie of the Year betting odds.
Offensive Rookie of the Year: The quarterback position remains one of the most important in the NFL and last year's 2024 NFL Draft saw Jayden Daniels win the offensive rookie of the year after being one of a record-tying six quarterbacks drafted <a href="https://www.benzinga.com/general/sports-betting/24/04/38501129/2024-nfl-draft-recap-quarterbacks-wide-receivers-detroit-set-records-who-will-win-rookie-o">in the first round.</a>
In the 2025 NFL Draft, there were only two quarterbacks drafted in the first round. Cam Ward is the number one overall pick by the Tennessee Titans. Jaxson Dart was selected later in the first round by the New York Giants.
In the last two seasons, the second overall pick and quarterback selected second in the draft has won the Rookie of the Year. Daniels won last year and C.J. Stroud won the year before that.
While Dart went later in the first round, he would fit that current trend of being the second quarterback drafted and the best rookie. Dart isn't expected to start in the 2025 NFL season with Russell Wilson brought in to lead the way, but who knows what will happen.
The big storyline in the 2025 NFL Draft was Colorado quarterback Shedeur Sanders falling out of the first round and dropping down to the fifth round where he was taken by the Cleveland Browns who now have five quarterbacks competing for the starting role including Sanders and fellow 2025 NFL Draft pick Dillon Gabriel, taken 94th overall in the third round.
Sanders will have a chip on his shoulder after falling in the draft, but given the Browns' depth at the position, he may not see the field next season.
Here are the current betting odds for the 2025 Offensive Rookie of the Year from DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>):
<ul>
<li>Ashton Jeanty (Raiders, RB): +200</li>
<li>Cam Ward (Titans, QB): +230</li>
<li>Travis Hunter (Jaguars, WR): +750</li>
<li>Tyler Shough (Saints, QB): +1,200</li>
<li>Tetairoa McMillan (Panthers, WR): +1,400</li>
<li>Omarion Hampton (Chargers, RB): +1,600</li>
<li>Quinshon Judkins (Browns, RB): +1,800</li>
<li>Shedeur Sanders (Browns, QB): +1,900</li>
<li>TreVeyon Henderson (Patriots, RB): +2,000</li>
<li>Colston Loveland (Bears, TE): +2,200</li>
</ul>
Of the top betting favorites, Shough, Judkins, Sanders and Henderson were all drafted after the first round. Over the last 10 seasons, the offensive rookie of the year has come from the first round eight times, with Alvin Kamara (second round) and Dak Prescott (fourth round) the exceptions.
Shough could be the immediate starter for the Saints and get a chance to compete for the award.
Another trend to watch will be the tight end position with Brock Bowers (Raiders) placing second in voting last year after breaking several records for the position. No tight end has ever won offensive rookie of the year.
Tight ends Loveland and Tyler Warren (+3,000) were first round picks who will be likely day one starters and could compete for the award as long as no quarterback has a huge season.
In the last 10 seasons, there have been five quarterbacks to win the award, along with three running backs and two wide receivers.
Travis Hunter is the other topic to watch as he is a two-way player and expected to play both wide receiver and cornerback for the Jaguars, who moved up to take him in the 2025 draft.
Fanduel, owned by Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>), also has betting lines of Hunter winning either rookie of the year award at odds of +440 and odds of him winning both offensive and defensive rookie of the year at +5,000.
With Hunter playing both sides of the ball, it may hurt his chances of winning either award, while playing both positions likely helped him winning the Heisman Trophy, which went to the best overall college football player for both offense and defense.
Across the last 10 drafts, the second overall pick won five Rookie of the Year awards for either offense or defense. That trend that could favor Hunter.
Ahead of the 2024 NFL season, first overall pick QB Caleb Williams (Bears) was the early favorite, while Daniels was listed with odds of +650.
Read Also: <a href="https://www.benzinga.com/general/sports/24/12/42521231/travis-hunter-wins-heisman-will-he-be-1-pick-in-2025-nfl-draft-what-betting-odds-history-show">Travis Hunter Wins Heisman, Will He Be #1 Pick In 2025 NFL Draft? What Betting Odds, History Show</a>
Defensive Rookie of the Year: On the other side of the ball, the defensive rookie of the year has been dominant by players taken in the first round.
Of the last 10 NFL Drafts, nine of the defensive rookie of the years came from the first round with the 19th pick or earlier. The one exception was a player taken 36th overall in the second round.
The defensive rookie of the year has been fairly evenly split by position with three linebackers winning, three defensive ends winning, three cornerbacks winning and one defensive lineman winning.
Here are the betting favorites for defensive rookie of the year at DraftKings:
<ul>
<li>Abdul Carter (Giants, Edge/DE): +250</li>
<li>Travis Hunter (Jaguars, CB): +750</li>
<li>Mykel Williams (49ers, Edge/DE): +900</li>
<li>Jalon Walker (Falcons, LB): +900</li>
<li>Jihaad Campbell (Eagles, LB): +1,200</li>
<li>Mason Graham (Browns, DT): +1,400</li>
<li>Shemar Stewart (Bengals, Edge/DE): +1,600</li>
<li>Mike Green (Ravens, Edge/DE)): +1,600</li>
</ul>
All the favorites were first round picks, outside of Green, who slid to the second round.
Last year, Jared Verse started the season ranked fourth at +1,100 odds after the NFL Draft before going on to win the defensive rookie of the year. Cater, who was considered the top prospect in the draft by some experts, is likely to stay the defensive favorite until the season begins.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43608426/super-bowl-lix-rematch-again-sportsbooks-list-eagles-chiefs-as-top-favorites-for-super-bowl-lx">Super Bowl LIX Rematch Again? Sportsbooks List Eagles, Chiefs As Top Favorites For Super Bowl LX</a></li>
</ul>
Image: Shutterstock

Sports Betting

Sports

DKNG

FLUT

NFL Rookie Of The Year Betting Odds: Shedeur Sanders Payout, Travis Hunter To Win Both Awards?

JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect JetBlue Airways to report an earnings per share (EPS) of $-0.62.
Investors in JetBlue Airways are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.09, leading to a 1.5% increase in the share price the following trading session.
Here's a look at JetBlue Airways's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.30</td>
<td>-0.25</td>
<td>-0.11</td>
<td>-0.52</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.16</td>
<td>0.08</td>
<td>-0.43</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-7.000000000000001%</td>
<td>-4.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866977_0.png" alt="eps graph" />
<h3>Market Performance of JetBlue Airways's Stock</h3>
Shares of JetBlue Airways were trading at $3.88 as of April 25. Over the last 52-week period, shares are down 28.7%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on JetBlue Airways</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on JetBlue Airways.
Analysts have provided JetBlue Airways with 8 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $4.44, suggesting a potential 14.43% upside.
<h3>Comparing Ratings with Competitors</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Allegiant Travel, Frontier Group Holdings and Sun Country Airlines, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Allegiant Travel, with an average 1-year price target of $64.43, suggesting a potential 1560.57% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Frontier Group Holdings, with an average 1-year price target of $7.02, suggesting a potential 80.93% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Sun Country Airlines, with an average 1-year price target of $14.5, suggesting a potential 273.71% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Allegiant Travel, Frontier Group Holdings and Sun Country Airlines, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>JetBlue Airways</td>
<td>Neutral</td>
<td>-2.06%</td>
<td>$426M</td>
<td>-1.67%</td>
</tr>
<tr>
<td>Allegiant Travel</td>
<td>Neutral</td>
<td>2.73%</td>
<td>$115.95M</td>
<td>-18.10%</td>
</tr>
<tr>
<td>Frontier Group Holdings</td>
<td>Neutral</td>
<td>12.46%</td>
<td>$83M</td>
<td>9.19%</td>
</tr>
<tr>
<td>Sun Country Airlines</td>
<td>Neutral</td>
<td>6.05%</td>
<td>$58.63M</td>
<td>2.39%</td>
</tr>
</tbody>
</table>

Key Takeaway:
JetBlue Airways ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is in the middle for Return on Equity.
<h3>About JetBlue Airways</h3>
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic &amp; Canada segment.
<h3>JetBlue Airways's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: JetBlue Airways's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -2.06%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: JetBlue Airways's net margin excels beyond industry benchmarks, reaching -1.93%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): JetBlue Airways's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -1.67%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): JetBlue Airways's ROA excels beyond industry benchmarks, reaching -0.26%. This signifies efficient management of assets and strong financial health.
Debt Management: JetBlue Airways's debt-to-equity ratio surpasses industry norms, standing at 3.46. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/JBLU/earnings">To track all earnings releases for JetBlue Airways visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JBLU

JetBlue Airways's Earnings Outlook

Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Sage Therapeutics to report an earnings per share (EPS) of $-0.99.
The market awaits Sage Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.20 in the last quarter, leading to a 0.42% drop in the share price on the following day.
Here's a look at Sage Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.36</td>
<td>-1.53</td>
<td>-1.66</td>
<td>-1.65</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.56</td>
<td>-1.53</td>
<td>-1.70</td>
<td>-1.80</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-24.0%</td>
<td>-11.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866969_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Sage Therapeutics were trading at $7.79 as of April 25. Over the last 52-week period, shares are down 44.51%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analysts' Perspectives on Sage Therapeutics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Sage Therapeutics.
A total of 4 analyst ratings have been received for Sage Therapeutics, with the consensus rating being Neutral. The average one-year price target stands at $9.5, suggesting a potential 21.95% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Regenxbio, Precigen and MeiraGTx Hldgs, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Regenxbio, with an average 1-year price target of $32.0, suggesting a potential 310.78% upside.</li>
<li>Analysts currently favor an Buy trajectory for Precigen, with an average 1-year price target of $6.0, suggesting a potential 22.98% downside.</li>
<li>Analysts currently favor an Buy trajectory for MeiraGTx Hldgs, with an average 1-year price target of $24.5, suggesting a potential 214.51% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
Within the peer analysis summary, vital metrics for Regenxbio, Precigen and MeiraGTx Hldgs are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sage Therapeutics</td>
<td>Neutral</td>
<td>-83.56%</td>
<td>$11.33M</td>
<td>-18.84%</td>
</tr>
<tr>
<td>Regenxbio</td>
<td>Buy</td>
<td>-4.50%</td>
<td>$14.90M</td>
<td>-18.25%</td>
</tr>
<tr>
<td>Precigen</td>
<td>Buy</td>
<td>-3.09%</td>
<td>$21K</td>
<td>-42.02%</td>
</tr>
<tr>
<td>MeiraGTx Hldgs</td>
<td>Buy</td>
<td>948.53%</td>
<td>$9.58M</td>
<td>-48.18%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Sage Therapeutics ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages indicating a decline. However, it ranks at the top for Return on Equity, showing a positive trend. Overall, Sage Therapeutics is positioned in the middle compared to its peers based on the provided metrics.
<h3>Delving into Sage Therapeutics's Background</h3>
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
<h3>Sage Therapeutics: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Sage Therapeutics faced challenges, resulting in a decline of approximately -83.56% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Sage Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -747.33%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -18.84%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Sage Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -16.38%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Sage Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/SAGE/earnings">To track all earnings releases for Sage Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SAGE

What to Expect from Sage Therapeutics's Earnings

ArcBest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here's a quick overview of what investors should know before the release.
Analysts are estimating that ArcBest will report an earnings per share (EPS) of $0.52.
The market awaits ArcBest's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.28, which was followed by a 0.0% drop in the share price the next day.
Here's a look at ArcBest's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.05</td>
<td>1.83</td>
<td>2.08</td>
<td>1.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.33</td>
<td>1.64</td>
<td>1.98</td>
<td>1.34</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-4.0%</td>
<td>-13.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866960_0.png" alt="eps graph" />
<h3>Performance of ArcBest Shares</h3>
Shares of ArcBest were trading at $58.42 as of April 25. Over the last 52-week period, shares are down 47.33%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Opinions on ArcBest</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding ArcBest.
With 13 analyst ratings, ArcBest has a consensus rating of Neutral. The average one-year price target is $95.54, indicating a potential 63.54% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Marten Transport, Werner Enterprises and Heartland Express, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Marten Transport, with an average 1-year price target of $19.0, suggesting a potential 67.48% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Werner Enterprises, with an average 1-year price target of $31.0, suggesting a potential 46.94% downside.</li>
<li>Analysts currently favor an Underperform trajectory for Heartland Express, with an average 1-year price target of $9.0, suggesting a potential 84.59% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Marten Transport, Werner Enterprises and Heartland Express, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ArcBest</td>
<td>Neutral</td>
<td>-8.07%</td>
<td>$82.75M</td>
<td>2.22%</td>
</tr>
<tr>
<td>Marten Transport</td>
<td>Outperform</td>
<td>-3.16%</td>
<td>$33.34M</td>
<td>0.56%</td>
</tr>
<tr>
<td>Werner Enterprises</td>
<td>Neutral</td>
<td>-8.18%</td>
<td>$90.90M</td>
<td>0.82%</td>
</tr>
<tr>
<td>Heartland Express</td>
<td>Underperform</td>
<td>-11.90%</td>
<td>$27.38M</td>
<td>-0.22%</td>
</tr>
</tbody>
</table>

Key Takeaway:
ArcBest ranks in the middle for revenue growth among its peers. It ranks at the top for gross profit. It ranks in the middle for return on equity.
<h3>All You Need to Know About ArcBest</h3>
ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.
<h3>Understanding the Numbers: ArcBest's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, ArcBest faced challenges, resulting in a decline of approximately -8.07% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: ArcBest's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.9% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): ArcBest's ROE excels beyond industry benchmarks, reaching 2.22%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ArcBest's ROA excels beyond industry benchmarks, reaching 1.2%. This signifies efficient management of assets and strong financial health.
Debt Management: ArcBest's debt-to-equity ratio is below the industry average at 0.31, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/ARCB/earnings">To track all earnings releases for ArcBest visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARCB

Uncovering Potential: ArcBest's Earnings Preview

NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect NeoGenomics to report an earnings per share (EPS) of $-0.01.
The market awaits NeoGenomics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.01 in the last quarter, leading to a 2.54% increase in the share price on the following day.
Here's a look at NeoGenomics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.03</td>
<td>0.01</td>
<td>0</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0.05</td>
<td>0.03</td>
<td>-0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>4.0%</td>
<td>18.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866952_0.png" alt="eps graph" />
<h3>Market Performance of NeoGenomics's Stock</h3>
Shares of NeoGenomics were trading at $10.27 as of April 25. Over the last 52-week period, shares are down 29.74%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Observations about NeoGenomics</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding NeoGenomics.
The consensus rating for NeoGenomics is Buy, derived from 5 analyst ratings. An average one-year price target of $17.0 implies a potential 65.53% upside.
<h3>Comparing Ratings with Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Astrana Health, OPKO Health and Pediatrix Medical Group, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Astrana Health, with an average 1-year price target of $47.4, suggesting a potential 361.54% upside.</li>
<li>Analysts currently favor an Buy trajectory for OPKO Health, with an average 1-year price target of $2.75, suggesting a potential 73.22% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Pediatrix Medical Group, with an average 1-year price target of $17.5, suggesting a potential 70.4% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary outlines pivotal metrics for Astrana Health, OPKO Health and Pediatrix Medical Group, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeoGenomics</td>
<td>Buy</td>
<td>10.57%</td>
<td>$77.26M</td>
<td>-1.69%</td>
</tr>
<tr>
<td>Astrana Health</td>
<td>Buy</td>
<td>88.43%</td>
<td>$50.48M</td>
<td>-0.98%</td>
</tr>
<tr>
<td>OPKO Health</td>
<td>Buy</td>
<td>0.95%</td>
<td>$84.66M</td>
<td>1.01%</td>
</tr>
<tr>
<td>Pediatrix Medical Group</td>
<td>Neutral</td>
<td>1.19%</td>
<td>$128.53M</td>
<td>4.07%</td>
</tr>
</tbody>
</table>

Key Takeaway:
NeoGenomics ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. For Return on Equity, NeoGenomics is at the bottom.
<h3>About NeoGenomics</h3>
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
<h3>A Deep Dive into NeoGenomics's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining NeoGenomics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.57% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: NeoGenomics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -8.91%, the company may face hurdles in effective cost management.
Return on Equity (ROE): NeoGenomics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -1.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): NeoGenomics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.93%, the company may face hurdles in achieving optimal financial returns.
Debt Management: NeoGenomics's debt-to-equity ratio is below the industry average. With a ratio of 0.67, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/NEO/earnings">To track all earnings releases for NeoGenomics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: NeoGenomics's Quarterly Earnings

AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that AtriCure will report an earnings per share (EPS) of $-0.22. 
The announcement from AtriCure is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.07, leading to a 6.54% drop in the share price on the subsequent day.
Here's a look at AtriCure's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.15</td>
<td>-0.19</td>
<td>-0.17</td>
<td>-0.23</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.08</td>
<td>-0.17</td>
<td>-0.17</td>
<td>-0.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>18.0%</td>
<td>-2.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866944_0.png" alt="eps graph" />
<h3>Market Performance of AtriCure's Stock</h3>
Shares of AtriCure were trading at $33.4 as of April 25. Over the last 52-week period, shares are up 39.55%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Views on AtriCure</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on AtriCure.
Analysts have provided AtriCure with 13 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $53.15, suggesting a potential 59.13% upside.
<h3>Comparing Ratings with Competitors</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Conmed, Omnicell and QuidelOrtho, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Conmed, with an average 1-year price target of $72.2, suggesting a potential 116.17% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Omnicell, with an average 1-year price target of $45.33, suggesting a potential 35.72% upside.</li>
<li>Analysts currently favor an Neutral trajectory for QuidelOrtho, with an average 1-year price target of $43.67, suggesting a potential 30.75% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary offers a detailed examination of key metrics for Conmed, Omnicell and QuidelOrtho, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>AtriCure</td>
<td>Outperform</td>
<td>16.64%</td>
<td>$92.62M</td>
<td>-3.36%</td>
</tr>
<tr>
<td>Conmed</td>
<td>Neutral</td>
<td>5.78%</td>
<td>$198.34M</td>
<td>3.56%</td>
</tr>
<tr>
<td>Omnicell</td>
<td>Neutral</td>
<td>18.56%</td>
<td>$141.76M</td>
<td>1.28%</td>
</tr>
<tr>
<td>QuidelOrtho</td>
<td>Neutral</td>
<td>-4.69%</td>
<td>$326.10M</td>
<td>-5.78%</td>
</tr>
</tbody>
</table>

Key Takeaway:
AtriCure ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, AtriCure's performance is strong in terms of revenue and profit growth, but it lags behind in generating returns for its shareholders.
<h3>About AtriCure</h3>
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
<h3>AtriCure: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining AtriCure's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.64% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AtriCure's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -12.53% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -3.36%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): AtriCure's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.54%, the company may face hurdles in achieving optimal financial returns.
Debt Management: AtriCure's debt-to-equity ratio is below the industry average. With a ratio of 0.17, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/ATRC/earnings">To track all earnings releases for AtriCure visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATRC

AtriCure Earnings Preview

Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Silicon Motion Technology to report an earnings per share (EPS) of $0.45.
Anticipation surrounds Silicon Motion Technology's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.07, leading to a 1.85% drop in the share price on the subsequent day.
Here's a look at Silicon Motion Technology's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.84</td>
<td>0.85</td>
<td>0.94</td>
<td>0.57</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.92</td>
<td>0.96</td>
<td>0.64</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-4.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866935_0.png" alt="eps graph" />
<h3>Market Performance of Silicon Motion Technology's Stock</h3>
Shares of Silicon Motion Technology were trading at $45.11 as of April 25. Over the last 52-week period, shares are down 40.39%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SIMO/earnings">To track all earnings releases for Silicon Motion Technology visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SIMO

Silicon Motion Technology's Earnings Outlook

Hillenbrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HI#NYSE">HI</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Hillenbrand to report an earnings per share (EPS) of $0.54.
Hillenbrand bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 7.3% drop in the share price the next day.
Here's a look at Hillenbrand's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.54</td>
<td>0.92</td>
<td>0.82</td>
<td>0.75</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.56</td>
<td>1.01</td>
<td>0.85</td>
<td>0.76</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>12.0%</td>
<td>-4.0%</td>
<td>-13.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866927_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Hillenbrand were trading at $22.52 as of April 25. Over the last 52-week period, shares are down 53.23%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/HI/earnings">To track all earnings releases for Hillenbrand visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Hillenbrand's Earnings Potential

Ribbon Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Ribbon Comms to report an earnings per share (EPS) of $0.00.
Ribbon Comms bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
In the previous earnings release, the company beat EPS by $0.04, leading to a 15.47% increase in the share price the following trading session.
Here's a look at Ribbon Comms's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.12</td>
<td>0.06</td>
<td>0.05</td>
<td>0</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.16</td>
<td>0.05</td>
<td>0.05</td>
<td>-0.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>15.0%</td>
<td>8.0%</td>
<td>-17.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866918_0.png" alt="eps graph" />
<h3>Tracking Ribbon Comms's Stock Performance</h3>
Shares of Ribbon Comms were trading at $3.61 as of April 25. Over the last 52-week period, shares are up 16.09%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Opinions on Ribbon Comms</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Ribbon Comms.
With 1 analyst ratings, Ribbon Comms has a consensus rating of Outperform. The average one-year price target is $6.0, indicating a potential 66.2% upside.
<h3>Comparing Ratings with Competitors</h3>
The below comparison of the analyst ratings and average 1-year price targets of Adtran Holdings, Applied Optoelectronics and Netgear, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Adtran Holdings, with an average 1-year price target of $13.33, suggesting a potential 269.25% upside.</li>
<li>Analysts currently favor an Buy trajectory for Applied Optoelectronics, with an average 1-year price target of $33.2, suggesting a potential 819.67% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Netgear, with an average 1-year price target of $29.0, suggesting a potential 703.32% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
Within the peer analysis summary, vital metrics for Adtran Holdings, Applied Optoelectronics and Netgear are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ribbon Comms</td>
<td>Outperform</td>
<td>11.02%</td>
<td>$140.07M</td>
<td>1.59%</td>
</tr>
<tr>
<td>Adtran Holdings</td>
<td>Buy</td>
<td>7.70%</td>
<td>$91.23M</td>
<td>-24.65%</td>
</tr>
<tr>
<td>Applied Optoelectronics</td>
<td>Buy</td>
<td>65.87%</td>
<td>$28.73M</td>
<td>-54.26%</td>
</tr>
<tr>
<td>Netgear</td>
<td>Outperform</td>
<td>-3.32%</td>
<td>$59.38M</td>
<td>-1.63%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Ribbon Comms ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.
<h3>Discovering Ribbon Comms: A Closer Look</h3>
Ribbon Communications Inc provides network solutions to service providers and enterprises. The company enables service providers and enterprises to modernize their communications networks and provide secure real-time communications solutions to their customers and employees. The company has two separate lines of business; the Cloud and Edge segment, and the IP Optical Networks segment. The majority of the revenue for the company is generated from its Cloud and Edge segment that provides secure and reliable software and hardware products, solutions, and services for VoIP communications, Voice Over LTE among others to service providers and enterprise customers. The company generates majority of its revenue from United States.
<h3>A Deep Dive into Ribbon Comms's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Ribbon Comms showcased positive performance, achieving a revenue growth rate of 11.02% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Ribbon Comms's net margin is impressive, surpassing industry averages. With a net margin of 2.53%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Ribbon Comms's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.59%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ribbon Comms's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.56% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.95, Ribbon Comms adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/RBBN/earnings">To track all earnings releases for Ribbon Comms visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RBBN

A Glimpse of Ribbon Comms's Earnings Potential

Press Releases

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Comments

Immix Biopharma

Notizie

Ultime notizie per Immix Biopharma (NASDAQ:IMMX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO